A detailed history of Janus Henderson Group PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 15,158,218 shares of ETNB stock, worth $121 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
15,158,218
Previous 13,276,110 14.18%
Holding current value
$121 Million
Previous $106 Million 5.48%
% of portfolio
0.06%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $13.9 Million - $18.2 Million
1,882,108 Added 14.18%
15,158,218 $112 Million
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $4.92 Million - $7.33 Million
672,728 Added 5.34%
13,276,110 $106 Million
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $30 Million - $50.8 Million
3,688,241 Added 41.37%
12,603,382 $147 Million
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $32.5 Million - $78.3 Million
4,885,938 Added 121.26%
8,915,141 $99.6 Million
Q3 2023

Nov 14, 2023

SELL
$15.06 - $19.41 $1.37 Million - $1.76 Million
-90,715 Reduced 2.2%
4,029,203 $62.2 Million
Q2 2023

Aug 14, 2023

BUY
$14.15 - $22.03 $5.29 Million - $8.24 Million
373,880 Added 9.98%
4,119,918 $78.1 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $28.6 Million - $46.2 Million
2,726,659 Added 267.48%
3,746,038 $57.1 Million
Q4 2022

Feb 14, 2023

BUY
$5.52 - $12.73 $1.28 Million - $2.95 Million
231,387 Added 29.36%
1,019,379 $13 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $7.0 $2.72 Million - $6.32 Million
-902,148 Reduced 53.38%
787,992 $4.56 Million
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $3.53 Million - $6.79 Million
1,690,140 New
1,690,140 $5.45 Million
Q4 2020

Feb 16, 2021

SELL
$23.16 - $28.08 $1.4 Million - $1.7 Million
-60,650 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$24.34 - $38.82 $1.48 Million - $2.35 Million
60,650 New
60,650 $1.56 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $370M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.